Journals / Klinik Tıp Bilimleri / 2019 / Cilt: 7 - Sayı: 3

Bariatric Surgery in the Treatment of Type 2 Diabetes Mellitus

Tip 2 Diyabet Tedavisinde Bariyatrik Cerrahinin Yeri

Pages
11–14
Publication Date
2019-04-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To place bariatric surgery into routine diabetes therapy guidelines; long-term results should be seen, indications must become exact, surgery’s place in the treatment of diabetes mustbe clarified as much as medical treatments; thus more time is needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractBariatric and metabolic surgeries, can be effective weightloss tools with a lifelong lifestyle support and annual medical monitoring at a minimum in morbid obesity, as asensible part of weight management program.
📊
Key Findings & Data:Bariatric surgery may be considered for adults with BMI 35 kg/m2 and type 2 diabetes, especially if diabetesor associated comorbidities are difficult to control with lifestyle changes and pharmacological therapy.
💡
Conclusion & Impact:To place bariatric surgery into routine diabetes therapy guidelines; long-term results should be seen, indications must become exact, surgery’s place in the treatment of diabetes mustbe clarified as much as medical treatments; thus more time is needed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Diyabetes mellitus · bariyat-rikcerrahi · obezite

Abstract

AbstractBariatric and metabolic surgeries, can be effective weightloss tools with a lifelong lifestyle support and annual medical monitoring at a minimum in morbid obesity, as asensible part of weight management program. Bariatric surgery may be considered for adults with BMI 35 kg/m2 and type 2 diabetes, especially if diabetesor associated comorbidities are difficult to control with lifestyle changes and pharmacological therapy. Although bariatric surgery has risks like mortality, early and late complications, morbidity and mortality related-to-surgery has significantly decreased. But; choosing the right patient, right surgeon and center and also appropriate technique is very important. To place bariatric surgery into routine diabetes therapy guidelines; long-term results should be seen, indications must become exact, surgery’s place in the treatment of diabetes mustbe clarified as much as medical treatments; thus more time is needed.

Özet

ÖzBariyatrik ve metabolik cerrahiler, ağır obezitede, mantıklı bir kilo yönetimi programının parçası olarak, ömür boyu süren bir yaşam tarzı desteği ve medikal monitorizasyon ile etkili kilo kaybı tedavileri olabilirler. Bariyatrik cerrahi VKİ 35 kg/m2 ve tip 2 diyabetli, özellikle diyabet ilişkili komorbiditeleri olan ve yaşam tarzı değişikliği ve farmakolojik tedavi ile kontrolü güç olan hastalarda uygulanabilir. Bariyatrik cerrahinin mortalite, erken ve geç komplikasyon riskleri bulunmasına rağmen, direkt cerrahiye bağlı morbidite ve mortalite ciddi şekilde düşmüştür. Ancak uygun hasta, doğru cerrah ve doğru merkez ile uygun teknik seçimi çok önemlidir. Rutin tedavi kılavuzlarında yer alması içinise; uzun vadedeki sonuçların görülmesi, endikasyonların kesinleştirilmesi ve cerrahinin diyabet tedavisindeki yerinin medikal tedaviler kadar netleştirilmesine, dolayısıyla zamana ihtiyaç vardır.

🔖

Cite This Article

AKBAŞ, U. D. F. (2019). Bariatric Surgery in the Treatment of Type 2 Diabetes Mellitus. Klinik Tıp Bilimleri, Cilt: 7 - Sayı: 3, 11–14. https://ajindex.com/articles/838218

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kaynaklar 1.Keidar A. Bariatricsurgeryfortype 2 diabetesreversal: Therisks.DiabetesCare 2011:34(2):S361-S266. 2.Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Top-lak H
  2. Obesity Management Task Force of the European Associa-tion for the Study of ObesityEuropean Guidelines for Obesity Ma-nagement in Adults.Obes Facts. 2015
  3. 8(6):402-24. 3.http://www.turkendokrin.org/files/file/OBEZITE_TTK_web.pdf TEMDObezite tanı ve tedavi kılavuzu-2014 Erişim tarihi:29.02.2016 4.Taşkın M,Zengin SÜ,Taşkın HE. Bariyatrik ve metabolik cerrahinin ta-rihçesi. Türkiye Klinikleri J Gen Surg-Special Topics 2015
  4. 8(3):1-5. 5. Bilen H.Bariyatrik cerrahide hasta seçiminde endokrinolojik değer-lendirme ve endikasyonlar. Bariyatrik ve metabolik cerrahinin tarih-çesi. Türkiye Klinikleri J Gen Surg-Special Topics 2015
  5. 8(3):12-15. 6. Mihmanlı M, Işıl RG, İdiz UO. Bariyatrik Cerrahi SonuçlarınaGenel Bakış. Türkiye Klinikleri J Gen Surg-Special Topics2015
  6. 8(3):6-11. 7. Erdem NZ. Metabolik ve Bariyatrik Cerrahide Nütrisyonel ve Me-tabolik Sorunların Çözümleri. Türkiye Klinikleri J Gen Surg-Spe cial Topics 2015
  7. 8(3):98-106. 8. http://www.idf.org/sites/default/files/DA-regional-factsheets-2014_FINAL.pdf IDF Diabetes Atlas 2014 Update 6th Edition Eu-rope At A Glance Erişim tarihi:29.02.2016 9. Grams J, Garvey WT. WeightLossandthePreventionandTreatment of Type2 Diabetes Using LifestyleTherapy, Pharmacotherapy, andBariatric-Surgery: Mechanisms of Action.CurrObesRep. 2015
  8. 4(2):287-302. 10.Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingro-ne G, et al. Bariatricsurgeryversusnon-surgicaltreatmentforobe-sity. Br J Sports Med. 2016
  9. 50(4):246. 11.Rubino F, Moo TA, Rosen DJ, Dakin GF, Pomp A. Diabetes sur-gery: a new approachto an olddisease.Diabetes Care.2009
  10. 32Suppl 2:S368-72 12.http://passthrough.fwnotify.net/download/581492/http://care.dia-betesjournals.org/site/misc/2016-Standards-of-Care.pdf Erişimtarihi:29.02.2016 AmericanDiabetesAssociationStandards ofMedicalCare in Diabetes 2016. Obesity Management fortheTre-atment of Type 2 Diabetes. DiabetesCare2016 39(1): 47-51. 13.Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric-surgerywithlong-termremission of type 2 diabetesandwithmicrovas-cularandmacrovascularcomplications.JAMA 2014
  11. 2297–2304. 14. Schauer PR, Bhatt DL, Kirwan JP, et al.
  12. STAMPEDEInvestiga-tors. Bariatricsurgeryversusintensivemedicaltherapyfordiabe-tesd 3-year outcomes. N Engl J Med 2014
  13. 2002–2013. 15. Still CD, Wood GC, Benotti P, et al.